We hypothesized that losartan would help in achieving clinical remission in CED (Camurati Engelmann Disease) patients by blocking TGFB1(transforming growth factor beta 1) with fewer side-effects than steroids.

CED characterised by progressive diaphyseal dysplasia is associated with debilitating bone pain in the limbs, muscle weakness, fatiguability and waddling gait.\[[@B1]\] Clinical manifestations are due to mutations in the TGFB1 gene leading to its over-expression and effect on bone. Losartan is an antagonist of TGFB1 and it slows the progress of aortic root dilatation inMarfan's syndrome by blocking the over-expression of TGFB1.\[[@B2]\] Steroids which have long been used for treatment of CED and been linked to long term side effects including those on growth, blood pressure and spinal osteoporosis.

A 10 year old child with mutation is in exon 4, position C652T causing an R218C amino acid substitution on chromosome 19q13 had severe limitation of activity since 4 years of age due to pain in the limbs. She underwent a physical examination, a dual energy xray absorptiometry scan(DEXA), pain score and 6 minute walk test prior to the start of losartan with a repeat of the tests 9 and 17 months later. She is being treated with losartan at a dose of 0.75mg/kg/day. Table [1](#T1){ref-type="table"}

  ---------------------------- ------- ------- -------
  Age at analysis(years)       9.3     10.1    10.7
  Cumulative pain score        9       1.75    0.25
  6 minute walk test(metres)   171     405     414
  DEXA weight(kgs)             17.42   17.01   20.01
  Height(cms)                  123.6   128.3   131.7
  Fat(gms)                     1702    1253    2693
  Lean(gms)                    14963   14957   16425
  BMC(gms)                     754.9   805     890.2
  A/G ratio                    0.29    0.23    0.39
  Total body fat%              10.2    7.7     14.1
  BMD gm/cm2                   0.845   0.873   0.887
  ---------------------------- ------- ------- -------

Losartan improves the quality of life in children with CED by reducing the bone pain along with improvement in their activity levels, fat & muscle mass, without major effects on growth, blood pressure and spinal osteoporosis.
